Nivolumab efficacy as cancer therapy: a metaanalysis of phase III randomized clinical trials

Conference paper

Salah Eddine El Herrag, Méghit Boumediène Khaled, Moulessehoul Soraya
13th Oncology Meeting Rabah Farhat, Algerian Soceity of Training & Research in Oncology and the Arab Medical Association Against Cancer , Sheraton Hotel, Algiers, 2021 Dec 16, pp. 38-39

13th Oncolgy Meeting Rabah Ferhat

Cite

APA Click to copy
Herrag, S. E. E., Khaled, M. B., & Soraya, M. (2021). Nivolumab efficacy as cancer therapy: a metaanalysis of phase III randomized clinical trials (pp. 38–39). Sheraton Hotel, Algiers: Algerian Soceity of Training & Research in Oncology and the Arab Medical Association Against Cancer .

Chicago/Turabian Click to copy
Herrag, Salah Eddine El, Méghit Boumediène Khaled, and Moulessehoul Soraya. “Nivolumab Efficacy as Cancer Therapy: a Metaanalysis of Phase III Randomized Clinical Trials.” In , 38–39. 13th Oncology Meeting Rabah Farhat. Sheraton Hotel, Algiers: Algerian Soceity of Training & Research in Oncology and the Arab Medical Association Against Cancer , 2021.

MLA Click to copy
Herrag, Salah Eddine El, et al. Nivolumab Efficacy as Cancer Therapy: a Metaanalysis of Phase III Randomized Clinical Trials. Algerian Soceity of Training & Research in Oncology and the Arab Medical Association Against Cancer , 2021, pp. 38–39.

BibTeX Click to copy

@inproceedings{salah2021a,
  title = {Nivolumab efficacy as cancer therapy: a metaanalysis of phase III randomized clinical trials},
  year = {2021},
  month = dec,
  day = {16},
  address = {Sheraton Hotel, Algiers},
  organization = {Algerian Soceity of Training & Research in Oncology and the Arab Medical Association Against Cancer },
  pages = {38-39},
  series = {13th Oncology Meeting Rabah Farhat},
  author = {Herrag, Salah Eddine El and Khaled, Méghit Boumediène and Soraya, Moulessehoul},
  month_numeric = {12}
}

Abstract
Introduction:
Nivolumab is an immune checkpoint inhibitor that binds to the PD-1 receptor expressed by activated T-cells unleashing, therefore, an immune response to tumor cells. We conducted a meta-analysis intending to investigate the efficacy of Nivolumab in the treatment of different types of cancer.
Methods:
The meta-analysis was performed in conformity with the PRISMA statement. PubMed, Cochrane, and the clinicaltrials.gov databases were searched up until August 15th, 2019 to identify Phase III randomized clinical trials. The included studies provided hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS). Additional analyses were undertaken including the risk of publication bias, influence analyses, and construction of Baujat plots. The statistical analyses were carried out with the R statistical program (version 3.6).
Results:
Sixteen phase III randomized controlled trials were included involving 8642 cancer patients. The trials examined the efficacy of Nivolumab in patients with melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), and gastric cancer (GC). For melanoma patients treated with Nivolumab compared to conventional therapies, HRs for OS and PFS were (0.72; 95% CI 0.56; 0.92) and (0.65; 95% CI 0.48; 0.88) respectively. OS was (0.75; 95% CI 0.60; 0.93) and PFS was (0.85; 95% CI 0.72; 1.02) for NSCLC patients. Patients with GC treated with Nivolumab benefited from 39% longer overall survival and 42% longer survival without tumor progression. Similar results were found for patients with SCCHN, and RCC. Overall survival and progression-free survival were significantly better among patients with melanoma, NSCLC, GC, SCCHN, and RCC.
Keywords: Neoplasms; Nivolumab; PD-L1; meta-analysis.

Poster: Nivolumab efficacy as cancer therapy: a metaanalysis of phase III randomized clinical trials